Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen 
Welcome,         Profile    Billing    Logout  
 11 Diseases   24 Trials   24 Trials   1081 News 


«12...234567891011121314»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    7100 TEZSPIRE (Tezepelumab-ekko): A Clinical Overview (Convention Center Exhibit Hall: Learning Theater 2) -  Sep 28, 2022 - Abstract #CHEST2022CHEST_4596;    
    Our expert will cover the efficacy and safety data and how it may apply in clinical practice. This is a non-CME event
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Product Theater 1 - Amgen and AstraZeneca : TEZSPIRE (tezepelumab-ekko): A Clinical Overview (Exhibit Hall (Upper Concourse), Kentucky International Convention Center) -  Sep 23, 2022 - Abstract #ACAAI2022ACAAI_538;    
    Description Please join Amgen and AstraZeneca as they share a different approach that may shift your point of view. Our expert will cover the efficacy and safety data and how it may apply in clinical practice.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Biomarker, Journal:  Clinical implications of asthma endotypes and phenotypes. (Pubmed Central) -  Sep 14, 2022   
    All of the current biologics, including the recently approved tezepelumab, were most effective with increased type 2 biomarkers, which identify exacerbation-prone asthma...The goal of identifying the optimal patient for a specific therapy remains elusive, but worthy of pursuit. In the interim, the availability of an increasing number of treatment options allows the clinician to help most of his or her patients.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    PASSAGE: A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF TEZEPELUMAB IN PATIENTS WITH SEVERE ASTHMA, INCLUDING UNDER-REPRESENTED GROUPS (Convention Center Exhibit Hall: Poster Area) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3669;    
    P2, P3, P4
    PASSAGE will further evaluate the effectiveness and safety of tezepelumab in a broad population of patients with severe asthma, in diverse, real-world clinical settings, including those who were under-represented in clinical trials. CLINICAL IMPLICATIONS: PASSAGE aims to build on observations from the PATHWAY and NAVIGATOR studies and to further describe the potential of tezepelumab to reduce exacerbations and improve lung function, asthma control and HRQoL in a real-world population of patients with severe, uncontrolled asthma, including those who are typically under-represented.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open:  SUNRISE: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (clinicaltrials.gov) -  Sep 7, 2022   
    P3,  N=207, Recruiting, 
    CLINICAL IMPLICATIONS: PASSAGE aims to build on observations from the PATHWAY and NAVIGATOR studies and to further describe the potential of tezepelumab to reduce exacerbations and improve lung function, asthma control and HRQoL in a real-world population of patients with severe, uncontrolled asthma, including those who are typically under-represented. Not yet recruiting --> Recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Fasenra (benralizumab) / AstraZeneca
    What Can We Learn from One Million Completed Daily Questionnaires about Patient Compliance and Burden? (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2044;    
    P3
    We used data collected from 1463 patients randomized in three respiratory clinical trials investigating benralizumab in patients with nasal polyps (NCT03401229) or tezepelumab in patients with asthma (NCT03347279 and NCT03406078). Detailed PRO analysis on compliance and response time of daily questionnaires in clinical trials provide significant insights on how to optimize longitudinal clinical studies in a patient-friendly manner.
  • ||||||||||  Journal:  Safety of biologics for atopic diseases during pregnancy. (Pubmed Central) -  Aug 24, 2022   
    Indeed, worsening of the underlying atopic disease during pregnancy appears to be more detrimental to the viability of the pregnancy. Given the small sample size and scarcity of studies, future research should include prospective studies with comparable control groups without exposure to biologics and multicenter registries for long-term follow-up.
  • ||||||||||  Review, Journal:  Pharmacological approaches to target type 2 cytokines in asthma. (Pubmed Central) -  Aug 24, 2022   
    Here, we discuss current knowledge on the structure and functions of these cytokines in asthma. We review preclinical and clinical data obtained with monoclonal antibodies (mAbs) targeting these cytokines or their receptors, as well as novel strategies under development, including bispecific mAbs, designed ankyrin repeat proteins (DARPins), small molecule inhibitors and vaccines targeting type 2 cytokines.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, astegolimab (RG 6149) / Amgen, Roche
    Newer Biologic Agents: Tezepelumab, Astegolimab (Convention Center 104DE) -  Aug 9, 2022 - Abstract #CHEST2022CHEST_1428;    
  • ||||||||||  40759 Ask the Experts: Biologics in Airway Disorders (Convention Center 104DE) -  Aug 9, 2022 - Abstract #CHEST2022CHEST_1425;    
    Newer Agents (Tezepelumab, Astegolimab) The attendees will be able to ask live questions as well as submit their questions anonymously in writing or virtually using an online platform. Audience Response Polling Learning Objective #1 Brief overview of mechanism of action and common uses of different biologic agents Learning Objective #2 Enhanced learner engagement and understanding of the biologic therapies Network/Committee Affiliation Airways
  • ||||||||||  Review, Journal:  Type 2 inflammation in asthma and other airway diseases. (Pubmed Central) -  Aug 6, 2022   
    Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases.
  • ||||||||||  Tezspire (tezepelumab) / AstraZeneca, Amgen, astegolimab (RG 6149) / Amgen, Roche
    Journal:  Investigational approaches for unmet need in severe asthma. (Pubmed Central) -  Jul 30, 2022   
    The recent approval of Tezepelumab presents a novel mAb therapeutic option for those with T2-low asthma...Endotypes associated with T2-low asthma are likely to be diverse but await validation. Investigational therapeutic approaches must, likewise, be diverse if the goal of remission is to become attainable for all those living with asthma.
  • ||||||||||  Journal:  Biologics in severe asthma: outcomes in clinical trials-similarities and differences. (Pubmed Central) -  Jul 23, 2022   
    This decision is mainly based on the individual characteristics of the patient, especially rate of exacerbations and use of systemic corticosteroids, but is also influenced by the presence of comorbidities and lung function impairment. No safety concerns have been raised around the use of these biologics.
  • ||||||||||  Tezspire (tezepelumab) / AstraZeneca, Amgen
    Review, Journal:  Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments. (Pubmed Central) -  Jul 7, 2022   
    The increased dependence on steroid-sparing biologic treatments in the 21 century has created a dilemma between identifying the patient's intrinsic biomarkers and their "life markers." With Tezepelumab being the most recent FDA-approved biologic for asthma, it is even more critical for asthma specialists to better understand and establish a framework to determine which biologic would work best for their patients. While cost and payor approvals limit access to certain asthma biologics, medical decisions on which biologic to select should be centered around shared decision-making, the rationale for biologic initiation, and critical biologic education to help achieve successful asthma control.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab) / AstraZeneca, Amgen
    Indirect comparison of dupilumab versus tezepelumab in patients with severe asthma (Ponce Foyer) -  Jun 26, 2022 - Abstract #EAC2022EAC_2;    
    P2, P3
    In adults and adolescents with severe, uncontrolled asthma, treatment with tezepelumab consistently reduced exacerbations across all seasons compared with placebo. In patients with ≥2 exacerbations in previous year, dupilumab may lead to greater magnitude of clinical response including exacerbation reduction, lung function improvement, and suppression of IgE, versus tezepelumab.
  • ||||||||||  Review, Journal:  Biologic Therapies in Pediatric Asthma. (Pubmed Central) -  Jun 25, 2022   
    The aim of the present study was to provide an overview of the current status of the latest evidence about all licensed monoclonal antibodies (mAbs) that have emerged and been applied to the field of asthma management. The innovative future targets are also briefly discussed.
  • ||||||||||  Tezspire (tezepelumab) / AstraZeneca, Amgen
    Journal:  One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. (Pubmed Central) -  Jun 22, 2022   
    P3
    Among exploratory outcomes, tezepelumab was associated with a low annualized asthma exacerbation rate over the study period (0.11/patient-year), improved lung function (mean [standard deviation] change from baseline of 0.075 [0.226] L in pre-dose/pre-bronchodilator forced expiratory volume in 1 s), and better asthma control versus baseline (responder rate: 71.4% at Week 52). Tezepelumab 210 mg SC Q4W in Japanese patients with severe uncontrolled asthma showed safety/tolerability profiles similar to international data, with low exacerbation rates and improvements in lung function and asthma control.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR (TP-9 in thematic poster area) -  Jun 22, 2022 - Abstract #ERS2022ERS_3834;    
    P3
    Conclusion Tezepelumab reduced exacerbations versus placebo irrespective of age at asthma onset. These data further support the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Effect of tezepelumab on a composite of severe asthma exacerbations and acute worsening events, CompEx, in the phase 3 NAVIGATOR study (8L) -  Jun 22, 2022 - Abstract #ERS2022ERS_3528;    
    P3
    The number of events and the annualized event rate were greater for CompEx than for severe asthma exacerbations; both were lower with tezepelumab than placebo (Table). Conclusion Tezepelumab reduced the CompEx event rate, a composite of severe asthma exacerbations and acute worsening events, versus placebo by a similar magnitude to the reduction in the rate of severe exacerbations, further demonstrating the efficacy of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Association of asthma genetic variants with asthma-associated traits reveals molecular networks of eosinophilic asthma (TP-6 in thematic poster area) -  Jun 22, 2022 - Abstract #ERS2022ERS_3092;    
    We identified genetically driven pathways regulating blood eosinophilia in asthma, with several genes already targeted by drugs currently available for eosinophilic asthma including IL4R (Dupilumab), and TSLP (Tezepelumab). Many asthma SNPs are also associated with blood eosinophilia, and genetically driven molecular networks of eosinophilic asthma were identified.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open, Trial completion date, Trial primary completion date:  WAYFINDER: Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma (clinicaltrials.gov) -  Jun 15, 2022   
    P3b,  N=323, Recruiting, 
    ConclusionTezepelumab reduced exacerbations versus placebo across all seasons in adults and adolescents with severe, uncontrolled asthma with high or low baseline BECs, consistent with the overall NAVIGATOR population. Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Oct 2023 --> Mar 2024